AlphAIAlphAI — Financial news for AI agents
benzinga.comSEP 221 min read$ERIC

Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

U.S. stock futures were mixed on Tuesday. Ericsson (NASDAQ:ERIC) fell 4.3% to $9.81 after a Morgan Stanley analyst downgraded it and cut the price target. Other stocks moving lower include Quest Diagnostics (NYSE:DGX), Rambus (NASDAQ:RMBS), and Lexeo Therapeutics (NASDAQ:LXEO).

Original reporting
benzinga.com
Published Sep 22, 2026, 12:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 12:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMarket movers
Primary signal
$ERIC
Bearish
high confidence
Mentioned
$ERIC · $LXEO
Relevance
6/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$ERICBearishMed
01

Why it matters

Downgrade of Ericsson and acquisition announcement by Lexeo are the primary new facts driving the price moves.

02

Market read

Fresh analyst downgrade and acquisition news create immediate trading opportunities in the affected stocks.

03

What to watch

Potential long‑term upside from Ericsson's 5G rollout and Lexeo's pipeline progress.

Relevance 6/10Novelty 6/10Timing: pre‑market today

Background

The article lists several US stocks that fell in pre‑market trading, highlighting analyst actions and corporate deals as catalysts.

Company-level read

Ticker impact

$ERICBearishHigh confidence
Context

Morgan Stanley downgraded Ericsson to Underweight and cut the price target to $9, causing a 4.3% pre‑market drop.

Expected impact

Further downside pressure in early trading.

Evidence & confidence

Downgrade is a fresh catalyst; price already fell 4.3% pre‑market.

$LXEOBearishMedium confidence
Context

Lexeo Therapeutics announced a deal to acquire Mantle Therapeutics and new collaborations in Friedreich Ataxia, sending the stock down 5.4% pre‑market.

Expected impact

Potential rebound if deal terms are viewed positively, but immediate sell pressure expected.

Evidence & confidence

Deal news is new but market reaction is a modest decline.

Market effects

Sector

Telecom equipment sector may see broader pressure as analyst sentiment tightens.

Regional

European tech stocks could face slight pullback in early US trading.

Global

Limited to US‑listed telecom and biotech names.

Counterpoint

What could challenge this read

If the downgrade is overly aggressive, the stock could rebound on short‑covering.

Key entities

  • Analyst Firm
    Morgan Stanley

    Issued downgrade and price target cut for Ericsson.

  • Target Company
    Mantle Therapeutics

    To be acquired by Lexeo Therapeutics.

Read at source← All news

Related articles

OCT 16
$ERICHighAI 8/10

Key facts: ERIC Q3: SEK59.5bn; Networks +9% (23.1%); Net 60.7bn

ERICSSON (ERIC) reported Q3 sales of SEK 59.5 billion, up 6% YoY, with adjusted EBITA of SEK 10.1 billion. Networks revenue rose 9% to SEK 38.7 billion. The company noted rising component costs and a flat RAN market affecting margins. Free cash flow pre-M&A was SEK 4.9 billion, with SEK 4.5 billion in buybacks this quarter. ERIC stock rose 8.7-10% intraday post-results.

tradingview.com2 min
OCT 15
$ERICHigh

European shares hit more than two-week high as sturdy earnings lift sentiment

European shares rose 0.4% to 640.16 points, their highest in over two weeks, driven by strong earnings and healthcare gains. Ericsson surged 6.8% after better-than-expected results. Tech stocks fell 1.5%, led by declines in Infineon, Soitec, and ASML. Mondi and Antofagasta dropped 7.9% and 4.1%, respectively, due to pricing and production issues. Traders expect an 87% chance of an ECB rate hike in December, per LSEG data.

businesstimes.com.sg2 min
OCT 15
$ERICHighAI 9/10

Ericsson Q3FY26 results: Revenue up 6%, EPS beats estimates by 29%

Ericsson reported Q3 revenue of $6.168B, up 6% YoY, and EPS of $0.18, beating estimates by 29%. Sales grew in all regions except the Americas, with Japan and India leading. Adjusted EBITDA margin rose to 17%. Management announced organizational changes and a cautious outlook due to cost pressures. The stock rose 10.9% in pre-market trading.

scanx.trade2 min
OCT 15
$ERICMed

Why Ericsson Stock Soared Today

Ericsson's stock rose 8.2% after Q3 earnings beat analyst expectations, with revenue up 5.9% to 59.5B SEK and EPS at 1.77 SEK. CEO Per Narvinger warned of flat RAN demand and rising costs, noting 2027 will be a 'transition period'.

fool.com4 min